| ID | 1171 |
| Name of the vaccine | Flagellin/F1/V |
| Microbe | Bacteria |
| Disease name | Plague |
| Name of bacteria | Yersinia pestis |
| Type of vaccine | Subunit |
| Nucleic acid content | Circular DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Plague vaccine, Flagellin/F1/V, phosphate-buffered saline, pH 6.2. |
| Name of the manufacturer | National Institute of Allergy and Infectious Diseases (NIAID) |
| Name of the manufacturing country | United States |
| Year of manufacture | 2014 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Clear, colourless solution |
| Dosage | Administered on days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). |
| Mechanism of action | Macrophage-protective antibody and significant CD4+ T-cell responses. |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Flagellin |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | Yes (enzootic from wild rodents and their fleas) |
| PubMed identifier | NA |
| Clinical trial number | NCT01381744 |
| Reference | https://www.nature.com/articles/s41541-020-0156-y |
| Other name | NA |
| Additional Links | NA
|